Obesity Market


Key Highlights:

 

  • Total prevalent cases of obesity in adults (>19 years) were 182.22 Million (M) and in children (5–19 years) were 7.85 million in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
  • In 2021, the total Obesity market size was USD 1,052 million which is expected to rise during the study period (2019–2032).
  • Obesity companies working in the market are Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others

 

Request a sample to unlock the CAGR for Obesity Market.

 

DelveInsight's "Obesity- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the obesity, historical and forecasted epidemiology as well as the obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Obesity market report provides current treatment practices, emerging drugs, Obesity market share of the individual therapies, current and forecasted obesity market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Obesity Understanding and Treatment Algorithm

The DelveInsight’s Obesity market report gives a thorough understanding of the disease.Obesity is defined as an abnormal or excessive accumulation of fat or adipose tissue in the body that presents a risk to health. The body mass index (BMI) is used to define obesity, which is calculated as weight (kg)/height (m2). A person with a body mass index greater than or equal to 30 is considered obese. It is the second most common cause of preventable death, which has its association with the risk of development of inflammatory components, directly and indirectly, related to cardiovascular disease, diabetes mellitus, respiratory problems, psychological issues, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. It imposes a significant public health epidemic that has progressively worsened over the past semi-centennial. An increase in obesity has been observed in children as well as adults of both genders and is prevalent in both developed and developing countries.

 

 

Compared to other chronic diseases, obesity results from an interaction between an individual’s genetic predisposition to weight gain and environmental influences. Gene discovery in the field of weight regulation and obesity has identified several major single-gene effects resulting in severe and early-onset obesity, as well as many more minor genes with more variable effects on weight and fat distribution, including age-of-onset and severity.

 

The most visible sign of obesity can be derived from the magnitude of excess adipose tissue fat, which is measured by taking anthropometric measurements such as body mass index (BMI), waist circumference, and others.

 

Body mass index, also known as Quetelet index, is defined as a person’s weight in kilograms divided by the square of his height in meters (kg/m2). For adults, a person is considered obese if they have BMI greater than or equal to 30. Whereas for children under 5 years of age, obesity is considered when weight-for-height is greater than three standard deviations above the WHO Child Growth Standards median. For children aged between 5–19 years of age, obesity is considered when weight-for-height is greater than two standard deviations above the WHO Growth Reference median

 

Diagnosis of obesity involves proper evaluation of the weight status, which considers many factors and uses various tools and diagnostic tests, including body mass index (BMI), waist circumference measurement, physical exams, and lab tests to check for comorbidities.

 

Obesity Treatment

Losing weight through healthy eating, increasing physical activity, and making other lifestyle changes are all common therapies for obesity. Some people may benefit from weight-management programs in order to lose weight or avoid regaining it. Some obese persons are either unable to drop enough weight to enhance their health or are unable to maintain their weight loss. Other therapies, such as weight-loss drugs, gadgets, or bariatric surgery, may be considered in such circumstances.

 

Within the first 6 months of treatment, it is recommended to decrease 5–10% of the body weight. It can help reduce the risk of developing obesity-related health problems, and improve health conditions associated with obesity, such as high blood pressure and high cholesterol levels.

 

So obesity can be managed by reducing calories and adopting healthier eating habits, physical activity, and weight loss medications like orlistat and phentermine.

Obesity Epidemiology

The obesity epidemiology section provides insights about historical and current obesity patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

In the year 2021, the total prevalent cases of obesity in adults (>19 years) were 182.22 Million (M) and in children (5–19 years) were 7.85 million in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

 

obesity prevalence

 

The Obesity epidemiology covered in the report provides historical as well as forecasted obesity epidemiology [segmented as total prevalent cases of obesity, total obesity patients seeking help, and total treated cases of obesity] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Obesity Epidemiology

The Obesity epidemiology segment also provides the obesity epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Obesity Drug Chapters

The drug chapter segment of the Obesity report encloses the detailed analysis of obesity marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the obesity clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Emerging Obesity Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for obesity treatment.

 

obesity market

Obesity Market Outlook

The obesity market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted obesity market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, barriers, and demand for better technology.

 

This segment gives a thorough detail of obesity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the obesity market in 7MM is expected to witness a major change in the study period 2019–2032.

 

Obesity market Key Findings

The obesity market size in the 7MM is expected to change during the study period 2019–2032. The Obesity therapeutic market in the seven major markets is expected to increase during the study period (2019–2032).

In 2021, the total Obesity market size was USD 1,052 million which is expected to rise during the study period (2019–2032).

 

The United States: Obesity Market Outlook

The total Obesity market size in the United States accounted for USD 847 million in 2021 which is expected to rise during the study period (2019–2032).

 

EU-5 Countries: Obesity Market Outlook

In EU5, the total Obesity market size was USD 185 million in 2021, which is expected to rise during the study period (2019–2032).

 

Japan: Obesity Market Outlook

In Japan, the total market size of obesity was USD 21 million in 2021, which is expected to rise during the study period (2019–2032).

 

obesity market outlook

Obesity Drug Uptake

This section focuses on the rate of uptake of the potential Obesity drugs recently launched in the obesity market or expected to get launched in the market during the study period 2019-2032. The analysis covers obesity market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Obesity Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses obesity key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers detailed information on collaborations, acquisition, and merger, licensing patent details, and other information for obesity emerging therapies.

Reimbursement Scenario in Obesity

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the obesity domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or obesity market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the obesity Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 1,052 million in 2021

Key Companies

Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma

Scope of the Obesity Market Report

  • The Obesity report covers the descriptive overview of obesity, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  • Comprehensive insight has been provided into the obesity epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for obesity are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the obesity market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global obesity market.

Obesity Report Highlights

  • In the coming years, the obesity market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence obesity R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for obesity. The launch of emerging therapies will significantly impact the obesity market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for obesity.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Obesity Report Insights

  • Obesity Patient Population
  • Obesity Therapeutic Approaches
  • Obesity Pipeline Analysis
  • Obesity Market Size and Trends
  • Obesity Market Opportunities
  • Impact of upcoming Obesity Therapies

Obesity Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Obesity Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Obesity Market
  • Obesity Drugs Uptake

Obesity Report Assessment

  • Current Treatment Practices
  • Obesity Unmet Needs
  • Obesity Pipeline Product Profiles
  • Obesity Market Attractiveness
  • Obesity Market Drivers and Barriers

Key Questions

Obesity Market Insights:

  • What was the obesity drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the obesity total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings of the market across 7MM and which country will have the largest obesity market size during the forecast period (2019-2032)?
  • At what CAGR, the obesity market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the obesity market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the obesity market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

 

Obesity Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of obesity?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical obesity patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of obesity in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM concerning the patient population about obesity?
  • Out of all 7MM countries, which country would have the highest prevalent population of obesity during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the obesity treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of obesity in the USA, Europe, and Japan?
  • What are the onesity marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of obesity?
  • How many therapies are in-development by each company for obesity treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for obesity treatment?
  • What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the obesity therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for obesity and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for obesity?
  • What are the global historical and forecasted markets of obesity?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the obesity market
  • To understand the future market competition in the obesity market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for obesity in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the obesity market
  • To understand the future market competition in the obesity market

Frequently Asked Questions

What is Obesity?
Obesity is a complicated condition characterized by an excess of body fat. Obesity is more than simply an aesthetic issue. It is a medical condition that raises the risk of developing other diseases and health issues, such as heart disease, diabetes, high blood pressure, and some malignancies. Some people struggle to lose weight for a variety of reasons. Obesity is typically caused by a combination of genetic, physiological, and environmental variables, as well as dietary, physical activity, and exercise decisions.
What is the Obesity Market Size in 7MM?
The total Obesity market size was accounted for USD 1,052 Million in the year 2021 and is estimated to grow during the study period (2019-2032).
Who are the leading companies in the Obesity Market Landscape?
The key players in the Obesity market who are in different phases of developing Obesity Therapies are - ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Company, and others.
What are the Key strengths of the Obesity Market Report?
Key strengths of the Obesity Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers, along with the upcoming market trends in the Obesity Market.
Which country is expected to account for the most significant prevalent cases for Obesity in the 7MM?
The United States is expected to account for the highest prevalent obesity cases.

1. Key Insights

2. Report Introduction

3. Obesity Market Overview at a Glance

3.1. Drug-class Share (%) Distribution of Obesity in 2019

3.2. Drug-class Share (%) Distribution of Obesity in 2032

4. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Signs and Symptoms

6.3. Risk Factors and Causes

6.4. Classification

6.5. Pathophysiology

6.5.1. Controlling Food Intake

6.5.2. Dysregulation of Lipid and Glucose Metabolism

6.5.3. Role of Adipocyte Inflammatory Secretagogues

6.6. Clinical Manifestations

6.7. Complications

7. Obesity Diagnosis

7.1. Diagnosis of Childhood Obesity

7.2. Diagnosis of Adolescent Obesity

7.3. Diagnosis of Morbid Obesity

7.4. Diagnosis of Metabolic Syndrome

7.5. Diagnostic Guidelines

7.5.1. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Diagnosis of Patients with Obesity

8. Treatment and Management

8.1. Treatment Algorithms

8.2. Treatment and Management Guidelines

8.2.1. The Endocrine Society Pharmacological Management of Obesity Guideline

8.2.2. European Society of Endocrinology Clinical Practice Guideline

8.2.3. The European Association for the Study of Obesity (EASO) Clinical Practice Guidelines

8.2.4. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Assumptions and Rationale: 7MM

9.3. Epidemiology Scenario

9.3.1. Total Prevalent Cases of Obesity in the 7MM

10. Obesity: Country-wise Epidemiology

10.1. The United States

10.1.1. Total Prevalent Cases of Obesity in the United States

10.1.2. Total Obesity patients seeking help in the United States

10.1.3. Total Treated Cases of Obesity in the United States

10.2. EU5 (Germany, France, Italy, Spain, and United Kingdom)

10.2.1. Total Prevalent Cases of Obesity in EU-5

10.2.2. Total Obesity patients seeking help in EU-5

10.2.3. Total Treated Cases of Obesity in the EU-5

10.3. Japan

10.3.1. Total Prevalent Cases of Obesity in Japan

10.3.2. Total Obesity patients seeking help in Japan

10.3.3. Total Treated Cases of Obesity in Japan

11. Patient Journey

12. Obesity Marketed Therapies

12.1. Key Competitors: Marketed Drugs

12.2. Xenical (orlistat): Hoffmann-La Roche/H2 Pharma

12.2.1. Product Description

12.2.2. Regulatory Milestones

12.2.3. Other Developmental Activity

12.2.4. Clinical Development

12.2.5. Clinical Trials Information

12.2.6. Safety and Efficacy

12.2.7. Product Profile

12.3. Qsymia (Phentermine - Topiramate): Vivus/ IEH Biopharma

12.3.1. Product Description

12.3.2. Regulatory Milestones

12.3.3. Other Developmental Activity

12.3.4. Clinical Development

12.3.5. Clinical Trials Information

12.3.6. Safety and Efficacy

12.3.7. Product Profile

12.4. Contrave (Naltrexon-Bupropion): Orexigen Therapeutics/Currax

12.4.1. Product Description

12.4.2. Regulatory Milestones

12.4.3. Other Developmental Activity

12.4.4. Clinical Development

12.4.5. Clinical Trials Information

12.4.6. Safety and Efficacy

12.4.7. Product Profile

12.5. Saxenda (Liraglutide): Novo Nordisk

12.5.1. Product Description

12.5.2. Regulatory Milestones

12.5.3. Other Developmental Activity

12.5.4. Clinical Development

12.5.5. Clinical Trials Information

12.5.6. Safety and Efficacy

12.5.7. Product Profile

12.6. Wegovy (Semaglutide): Novo Nordisk

12.6.1. Product Description

12.6.2. Regulatory Milestones

12.6.3. Other Developmental Activity

12.6.4. Clinical Development

12.6.5. Clinical Trials Information

12.6.6. Safety and Efficacy

12.6.7. Product Profile

12.7. Imcivree (Setmelanotide): Rhythm Pharmaceuticals

12.7.1. Product Description

12.7.2. Regulatory Milestones

12.7.3. Other Developmental Activity

12.7.4. Clinical Development

12.7.5. Clinical Trials Information

12.7.6. Safety and Efficacy

12.7.7. Product Profile

13. Emerging Obesity Therapies

13.1. Key Competitors: Emerging Therapies

13.2. Key Competitors: Other Notable Emerging Therapies

13.3. Semaglutide oral: Novo Nordisk

13.3.1. Product Description

13.3.2. Clinical Development

13.3.3. Product Profile

13.4. Tirzepatide: Eli Lilly and Company

13.4.1. Product Description

13.4.2. Clinical Development

13.4.3. Clinical Trials Information

13.4.4. Safety and Efficacy

13.4.5. Product Profile

13.4.6. Analysts’ Views

13.5. Cotadutide: MedImmune

13.5.1. Product Description

13.5.2. Other Developmental Activities

13.5.3. Clinical Development

13.5.4. Clinical Trials Information

13.5.5. Safety and Efficacy

13.5.6. Product Profile

13.5.7. Analysts’ Views

13.6. BI 456906: Boehringer Ingelheim

13.6.1. Product Description

13.6.2. Other Developmental Activities

13.6.3. Clinical Development

13.6.4. Clinical Trials Information

13.6.5. Safety and Efficacy

13.6.6. Product Profile

13.6.7. Analysts’ Views

13.7. RZL-012: Raziel Therapeutics

13.7.1. Product Description

13.7.2. Other Developmental Activities

13.7.3. Clinical Development

13.7.4. Clinical Trials Information

13.7.5. Safety and Efficacy

13.7.6. Product Profile

13.7.7. Analysts’ Views

13.8. NNC0174-0833: Novo Nordisk

13.8.1. Product Description

13.8.2. Clinical Development

13.8.3. Clinical Trials Information

13.8.4. Safety and Efficacy

13.8.5. Product Profile

13.8.6. Analysts’ Views

13.9. Pemvidutide: Altimmune

13.9.1. Product Description

13.9.2. Other Developmental Activities

13.9.3. Clinical Development

13.9.4. Clinical Trials Information

13.9.5. Safety and Efficacy

13.9.6. Product Profile

13.9.7. Analysts’ Views

13.10. Tesomet: Saniona

13.10.1. Product Description

13.10.2. Other Developmental Activities

13.10.3. Clinical Development

13.10.4. Clinical Trials Information

13.10.5. Safety and Efficacy

13.10.6. Product Profile

13.10.7. Analysts’ Views

13.11. Xla1: YSOPIA Bioscience

13.11.1. Product Description

13.11.2. Other Developmental Activities

13.11.3. Clinical Development

13.11.4. Clinical Trials Information

13.11.5. Safety and Efficacy

13.11.6. Product Profile

13.11.7. Analysts’ Views

13.12. IBI362: Innovent Biologics

13.12.1. Product Description

13.12.2. Other Developmental Activities

13.12.3. Clinical Development

13.12.4. Clinical Trials Information

13.12.5. Safety and Efficacy

13.12.6. Product Profile

13.12.7. Analysts’ Views

13.13. HSG4112: Glaceum

13.13.1. Product Description

13.13.2. Clinical Development

13.13.3. Clinical Trials Information

13.13.4. Safety and Efficacy

13.13.5. Product Profile

13.13.6. Analysts’ Views

13.14. S-237648: Shionogi

13.14.1. Product Description

13.14.2. Clinical Development

13.14.3. Clinical Trials Information

13.14.4. Safety and Efficacy

13.14.5. Product Profile

13.14.6. Analysts’ Views

13.15. ARD-101: Aardvark Therapeutics

13.15.1. Product Description

13.15.2. Other Developmental Activities

13.15.3. Clinical Development

13.15.4. Safety and Efficacy

13.15.5. Product Profile

13.15.6. Analysts’ Views

13.16. LY 3437943: Eli Lilly and Company

13.16.1. Product Description

13.16.2. Clinical Development

13.16.3. Clinical Trials Information

13.16.4. Safety and Efficacy

13.16.5. Product Profile

13.16.6. Analysts’ Views

13.17. Leucine/sildenafil: NuSirt Biopharma

13.17.1. Product Description

13.17.2. Clinical Development

13.17.3. Clinical Trials Information

13.17.4. Safety and Efficacy

13.17.5. Product Profile

13.17.6. Analysts’ Views

13.18. MBL949: Novartis

13.18.1. Product Description

13.18.2. Clinical Development

13.18.3. Clinical Trials Information

13.18.4. Product Profile

13.19. TG103: CSPC Baike (Shandong) Biopharmaceutical

13.19.1. Product Description

13.19.2. Other Developmental Activities

13.19.3. Clinical Development

13.19.4. Clinical Trials Information

13.19.5. Product Profile

13.20. SHR20004: Jiangsu HengRui Medicine

13.20.1. Product Description

13.20.2. Clinical Development

13.20.3. Clinical Trials Information

13.20.4. Product Profile

13.21. CT-868: Carmot Therapeutics

13.21.1. Product Description

13.21.2. Other Developmental Activities

13.21.3. Clinical Development

13.21.4. Clinical Trials Information

13.21.5. Product Profile

13.22. PF-06882961: Pfizer

13.22.1. Product Description

13.22.2. Clinical Development

13.22.3. Clinical Trials Information

13.22.4. Product Profile

13.23. NNC0165-1875: Novo Nordisk

13.23.1. Product Description

13.23.2. Clinical Development

13.23.3. Clinical Trials Information

13.23.4. Product Profile

13.24. XW 003: Sciwind Biosciences

13.24.1. Product Description

13.24.2. Other Developmental Activities

13.24.3. Clinical Development

13.24.4. Clinical Trials Information

13.24.5. Product Profile

13.25. LY3502970: Eli Lilly and Company

13.25.1. Product Description

13.25.2. Clinical Development

13.25.3. Clinical Trials Information

13.25.4. Product Profile

13.26. EMP16-01: Empros Pharma

13.26.1. Product Description

13.26.2. Other Developmental Activities

13.26.3. Clinical Development

13.26.4. Clinical Trials Information

13.26.5. Safety and Efficacy

13.26.6. Product Profile

13.26.7. Analysts’ Views

13.27. NNC-0480-0389: Novo Nordisk

13.27.1. Product Description

13.27.2. Clinical Development

13.27.3. Clinical Trials Information

13.27.4. Product Profile

13.28. NNC0247 0829: Novo Nordisk

13.28.1. Product Description

13.28.2. Clinical Development

13.28.3. Clinical Trials Information

13.28.4. Product Profile

14. Conjoint Analysis

15. Obesity: 7 Major Market Analysis

15.1. Key Findings

15.2. Potential of Current and Emerging therapies

15.3. Market Size of Obesity in the 7MM

15.4. Market Size of Obesity by Therapies

15.5. Market Size in the United States

15.5.1. Total Market Size of Obesity

15.5.2. Market Size of Obesity by Therapies in the United States

15.6. Market Size in EU-5

15.6.1. Total Market Size of Obesity

15.6.2. Market Size of Obesity by Therapies

15.7. Market Size of Obesity in Japan

15.7.1. Total Market Size of Obesity

15.7.2. Market Size of Obesity by Therapies

16. Reimbursement and Market access

16.1. United States

16.2. Europe

16.3. Japan

17. KOL Views

18. Obesity Market Drivers

19. Obesity Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

22.1. Bibliography

22.2. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Table

Table 1: Key Events

Table 2: Classification of Overweight and Obesity, and Associated Disease Risk

Table 3: Diagnostic Criteria for Metabolic Syndrome*

Table 4: Diagnostic and Medical management of Obesity

Table 5: Total Prevalent Cases of Obesity in the 7MM (2019–2032)

Table 6: Total Prevalent Cases of Obesity in the United States (2019–2032)

Table 7: Total Obesity patients seeking help in the United States (2019–2032)

Table 8: Total Treated cases of Obesity in the United States (2019–2032)

Table 9: Total Prevalent Cases of Obesity in EU-5 (2019–2032)

Table 10: Total Obesity patients seeking help in EU5 (2019–2032)

Table 11: Total Treated cases of obesity in EU5 (2019–2032)

Table 12: Total Diagnosed Prevalent Cases of Obesity in Japan (2019–2032)

Table 13: Total Obesity patients seeking help in Japan (2019–2032)

Table 14: Total Treated cases of Obesity in Japan (2019–2032)

Table 15: Key competitors: Marketed drugs

Table 16: Xenical (orlistat), Clinical Trial Description, 2022

Table 17: Qsymia (phentermine-topiramate), Clinical Trial Description, 2022

Table 18: Contrave (naltrexone-bupropion), Clinical Trial Description, 2022

Table 19: Saxenda (liraglutide), Clinical Trial Description, 2022

Table 20: Wegovy (Simaglutide), Clinical Trial Description, 2022

Table 21: Imcivree (setmelanotide)/ RM-493, Clinical Trial Description, 2022

Table 22: Key Emerging Therapies

Table 23: Other Notable Emerging Therapies

Table 24: Semaglutide Oral, Clinical Trial Description, 2022

Table 25: Tirzepatide, Clinical Trial Description, 2022

Table 26: Cotadutide, Clinical Trial Description, 2022

Table 27: BI 456906, Clinical Trial Description, 2022

Table 28: RZL-012, Clinical Trial Description, 2022

Table 29: NNC0174-0833, Clinical Trial Description, 2022

Table 30: Pemvidutide, Clinical Trial Description, 2022

Table 31: Tesomet, Clinical Trial Description, 2022

Table 32: Xla1, Clinical Trial Description, 2022

Table 33: IBI362, Clinical Trial Description, 2022

Table 34: HSG4112, Clinical Trial Description, 2022

Table 35: S-237648, Clinical Trial Description, 2022

Table 36: ARD-101, Clinical Trial Description, 2022

Table 37: LY 3437943, Clinical Trial Description, 2022

Table 38: Leucine/sildenafil, Clinical Trial Description, 2022

Table 39: MBL949, Clinical Trial Description, 2022

Table 40: TG103, Clinical Trial Description, 2022

Table 41: SHR20004, Clinical Trial Description, 2022

Table 42: CT-868, Clinical Trial Description, 2022

Table 43: PF-06882961, Clinical Trial Description, 2022

Table 44: NNC0165-1875, Clinical Trial Description, 2021

Table 45: XW003, Clinical Trial Description, 2022

Table 46: LY3502970, Clinical Trial Description, 2022

Table 47: EMP16-01, Clinical Trial Description, 2022

Table 48: NNC-0480-0389 , Clinical Trial Description, 2022

Table 49: NNC0247 0829, Clinical Trial Description, 2022

Table 50: 7MM Market Size of Obesity in the 7MM in USD Million (2019–2032)

Table 51: 7MM Market Size of Obesity by Therapies in USD Million (2019–2032)

Table 52: Market Size of Obesity in the United States, in USD Million (2019–2032)

Table 53: Market Size of Obesity by Therapies in the United States, in USD Million (2019–2032)

Table 54: Market Size of Obesity in EU-5, in USD Million (2019–2032)

Table 55: Market Size of Obesity by Therapies in EU-5, in USD Million (2019–2032)

Table 56: Market Size of Obesity in Japan, in USD Million (2019–2032)

Table 57: Market Size of Obesity by Therapies in Japan, in USD Million (2019–2032)

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Symptoms of Obesity in Adults

Figure 3: Symptoms of Obesity in Children and Adolescents

Figure 4: Symptoms of Morbid Obesity

Figure 5: Risk Factors of Obesity

Figure 6: Causes of Obesity

Figure 7: Neural Pathways and Systems Controlling Ingestive Behavior and Energy Balance

Figure 8: Role of lipotoxicity and inflammation on obesity

Figure 9: Role of inflammation and immune dysfunction in obesity

Figure 10: Medical Complications of Obesity

Figure 11: Clinical care pathway for overweight and obese adults

Figure 12: Total Prevalent Cases of Obesity in Adults in the 7MM (2019–2032)

Figure 13: Total Prevalent Cases of Obesity in Children in the 7MM (2019–2032)

Figure 14: Total Prevalent Cases of Obesity in Adults in the United States (2019–2032)

Figure 15: Total Prevalent Cases of Obesity in Children in the United States (2019–2032)

Figure 16: Total Obesity patients seeking help in adults in the United States (2019–2032)

Figure 17: Total Obesity patients seeking help in children in the United States (2019–2032)

Figure 18: Total Treated Cases of Obesity in Adults the United States (2019–2032)

Figure 19: Total Treated Cases of Obesity in Children in the United States (2019–2032)

Figure 20: Total Prevalent Cases of Obesity in Adults in EU-5 (2019–2032)

Figure 21: Total Prevalent Cases of Obesity in Children in EU-5 (2019–2032)

Figure 22: Total Obesity patients seeking help in Adults in EU-5 (2019–2032)

Figure 23: Total Obesity patients seeking help in Children in EU-5 (2019–2032)

Figure 24: Total Treated Cases of Obesity in Adults in EU5 (2019–2032)

Figure 25: Total Treated Cases of Obesity in Children in EU5 (2019–2032)

Figure 26: Total Prevalent Cases of Obesity in Adults Japan (2019–2032)

Figure 27: Total Prevalent Cases of Obesity in Children Japan (2019–2032)

Figure 28: Total Obesity patients seeking help in Adults in Japan (2019–2032)

Figure 29: Total Children Obesity patients seeking help in Adults in Japan (2019–2032)

Figure 30: Total Treated Cases of Obesity in Adults Japan (2019–2032)

Figure 31: Total Treated Cases of Obesity in Children in Japan (2019–2032)

Figure 32: Percentage of Patients Losing ≥5% and ≥10% of Body Weight From Randomization After 1-year Treatment*

Figure 33: Mean Change in Risk Factors From Randomization Following 1-year Treatment* Population as a Whole

Figure 34: Percentage of Patients Losing ≥ 5% and ≥ 10% of Body Weight From Randomization After 2-year Treatment*

Figure 35: Mean Change From Baseline Body Weight (Kg) Over Time*

Figure 36: Mean Change in Risk Factors From Randomization Following 4-year Treatment*

Figure 37: Incidence Rate of Diabetes at Year 4 by OGTT Status at Baseline*

Figure 38: Percentages of Patients With ≥5% and ≥10% Decrease in Body Mass Index and Body Weight After 1-year Treatment* (Protocol NM16189)

Figure 39: Weight Loss at Year 1 in Study 1 and 2

Figure 40: Change in Weight in 56-week Trials With Contrave (ITT/LOCF*)

Figure 41: Change in Markers Of Cardiovascular and Metabolic Parameters From Baseline in 56-week Trials With Contrave 32 mg/360 mg (COR-I and COR-BMOD)*

Figure 42: Changes in Cardiometabolic Parameters and Waist Circumference in Patients With Type 2 Diabetes Mellitus in a 56-week Trial With Contrave 32 mg/360 mg (COR-Diabetes)

Figure 43: Changes in Weight at Week 56 for Studies 1, 2, and 3

Figure 44: Changes in Weight at Week 56 and Week 160 for study 1 (Subset of Patients With Abnormal Blood Glucose at Randomization)

Figure 45: Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 1 (Patient Without Diabetes)

Figure 46: Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 2 (Patient With Diabetes Mellitus)

Figure 47: The Time Course of Change in BMI SDS With Saxenda and Placebo From Baseline Through Week 56

Figure 48: Changes in Weight and BMI at Week 56 for Study 4 (Pediatric Patients Ages 12 to Less Than 18)

Figure 49: Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 4 (Pediatric Patients Ages 12 to Less Than 18)

Figure 50: Body Weight (kg) – Proportion of Patients Achieving at least 10% Weight Loss From Baseline at 1-year in Study 1 and Study 2

Figure 51: Body Weight (kg) – Proportion of Patients Achieving at least 10% Weight Loss From Baseline at 1 year in Study 1 and Study 2

Figure 52: Mean Percentage Change in Body Weight From Baseline by Visit (Study 1 [n=9] and

Figure 53: Daily Hunger Scores – Change from Baseline at 1-year in Subjects Aged ≥12 Years in Study 1 and Study 2 With Available Hunger Data

Figure 54: Market Size of Obesity in the 7MM, USD Million (2019–2032)

Figure 55: 7MM Market Size of Obesity by Therapies in USD Million (2019–2032)

Figure 56: Market Size of Obesity in the United States, USD Million (2019–2032)

Figure 57: Market Size of Obesity by Therapies in the United States, in USD Million (2019–2032)

Figure 58: Market Size of Obesity in EU-5, USD Million (2019–2032)

Figure 59: Market Size of Obesity by Therapies in EU-5, in USD Million (2019–2032)

Figure 60: Market Size of Obesity in Japan, USD Million (2019–2032)

Figure 61: Market Size of Obesity by Therapies, in Japan in USD Million (2019–2032)

Figure 62: Market Drivers

Figure 63: Market Barriers

Figure 64: Unmet Needs

  • Novo Nordisk
  • Eli Lilly and Company
  • MedImmune
  • Boehringer Ingelheim
  • Raziel Therapeutics
  • Altimmune
  • Saniona
  • YSOPIA Bioscience
  • Innovent Biologics
  • Glaceum
  • Shionogi
  • Aardvark Therapeutics
  • NuSirt Biopharma
  • Novartis
  • CSPC Baike (Shandong) Biopharmaceutical
  • Jiangsu HengRui Medicine
  • Carmot Therapeutics
  • Pfizer
  • Sciwind Biosciences
  • Empros Pharma

 

 

Forward to Friend

Need A Quote